Trial
NCT01032915
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Non-infectious Uveitis
Intervention
AIN457
Why stopped
Results of a planned interim analysis did not show significant effects for any of the 3 AIN dose regimens versus placebo on any primary or secondary endpoint
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-11-05